Status:
TERMINATED
HepaStem Long-Term Safety Registry
Lead Sponsor:
Cellaion SA
Conditions:
Urea Cycle Disorder
Crigler-Najjar Syndrome
Eligibility:
All Genders
5-75 years
Brief Summary
All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences
Eligibility Criteria
Inclusion
- All patients having received at least one infusion of HepaStem during a previous interventional clinical study conducted by Promethera.
Exclusion
- Patients who received an OLT and completed 6-month FU documentation prior to the start of the PROLONGSTEM study.
- Patients who have received mature liver cells or stem cells other than HepaStem prior to the start of the PROLONGSTEM study.
Key Trial Info
Start Date :
April 4 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 23 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03343756
Start Date
April 4 2018
End Date
May 23 2024
Last Update
May 29 2024
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Erasme
Anderlecht, Belgium, 1070
2
Antwerp University Hospital
Antwerp, Belgium, 2650
3
Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann
Brussels, Belgium, 1020
4
UCL
Brussels, Belgium, 1200